@article {Casta{\~n}o5ra13, author = {Casta{\~n}o, Ana P. and Lin, Shuei-Liong and Surowy, Teresa and Nowlin, Brian T. and Turlapati, Swathi A. and Patel, Tejas and Singh, Ajay and Li, Shawn and Lupher, Mark L. and Duffield, Jeremy S.}, title = {Serum Amyloid P Inhibits Fibrosis Through FcγR-Dependent Monocyte-Macrophage Regulation in Vivo}, volume = {1}, number = {5}, pages = {5ra13--5ra13}, year = {2009}, doi = {10.1126/scitranslmed.3000111}, publisher = {American Association for the Advancement of Science}, abstract = {New therapies that target chronic inflammation with fibrosis are urgently required. Increasing evidence points to innate activation of inflammatory cells in driving chronic organ fibrosis. Serum amyloid P is a naturally circulating soluble pattern recognition receptor, a member of the family of pentraxin proteins. It links danger-associated molecular pattern recognition to Fcγ receptor{\textendash}mediated phagocytosis. Here we show that fibrosis progression in the mouse kidney is significantly inhibited by therapeutic administration of human serum amyloid P, regulated by activating Fcγ receptors, and dependent on inflammatory monocytes and macrophages, but not fibrocytes. Human serum amyloid P{\textendash}mediated inhibition of mouse kidney fibrosis correlated with specific binding of human serum amyloid P to cell debris and with subsequent suppression of inflammatory monocytes and kidney macrophages in vitro and in vivo, and was dependent on regulated binding to activating Fcγ receptors and interleukin-10 expression. These studies uncover previously unidentified roles for Fcγ receptors in sterile inflammation and highlight serum amyloid P as a potential antifibrotic therapy through local generation of interleukin-10.}, issn = {1946-6234}, URL = {https://stm.sciencemag.org/content/1/5/5ra13}, eprint = {https://stm.sciencemag.org/content/1/5/5ra13.full.pdf}, journal = {Science Translational Medicine} }